EFFECTS OF FERULIC ACID ON HUMAN SERUM PARAOXONASE ENZYME PURIFIED BY THREE PHASE PARTITIONING

Year 2021, Volume: 1 Issue: 1, 1 - 7, 30.12.2021

Semra Çiçek

Abstract

Human serum paraoxonase 1 (PON1) is a enzyme which inhibits macrophage cholesterol biosynthesis, metabolizes peroxides of cholesterol esters and reduces cholesterol efflux into macrophages. Therefore, it is speculated to play a role in several human diseases including diabetes mellitus and atherosclerosis. In this study, paraoxonase enzyme was first purified from human serum with three-phase partitioning method (TPP), also kinetic, characterization studies, and effects of ferulic acid were carried out. TPP purification process was performed in three stages. In first stage, PON1 was exposed to 60-80% ammonium sulfate precipitation, in the second stage, 1,0:0,5 ratio of human serum/ t-butanol and 20% ammonium sulfate saturation were used. In the third stage, the second TPP stage made over the intermediate, PON1 enzyme was purified from human serum with 49,87% recovery and 182,66 purification fold using constant ratio of human serum:t-butanol. In studies of the purified enzyme for kinetic properties, optimum pH, stable pH, optimum temperature, stable temperature were determined as 8,1, 7,0, 37°C, 20°C, respectively. Molecular weight of enzyme was found to be 45 kDa from Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE). In addition, the inhibition effects of ferulic acid on the purified PON1 enzyme were investigated and Lineweaver Burk plots were obtained.

Keywords

Paraoxonase 1, Three-Phase Partitioning Method, Ferulic Acid

References

• References [1] Précourt, L. P., Amre, D., Denis, M. C., Lavoie, J. C., Delvin, E., Seidman, E., & Levy, E. (2011). The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis, 214(1), 20-36.
• [2] Draganov, D. I., Teiber, J. F., Speelman, A., Osawa, Y., Sunahara, R., & La Du, B. N. (2005). Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. Journal of lipid research, 46(6), 1239-1247.
• [3] Blaha-Nelson, D., Krüger, D. M., Szeler, K., Ben-David, M., & Kamerlin, S. C. L. (2017). Active site hydrophobicity and the convergent evolution of paraoxonase activity in structurally divergent enzymes: the case of serum paraoxonase 1. Journal of the American Chemical Society, 139(3), 1155-1167.
• [4] Shunmoogam, N., Naidoo, P., & Chilton, R. (2018). Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vascular health and risk management, 14, 137.
• [5] Draganov, D. I., & La Du, B. N. (2004). Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's archives of pharmacology, 369(1), 78-88.
• [6] Mackness, B., Davies, G. K., Turkie, W., Lee, E., Roberts, D. H., Hill, E., ... & Mackness, M. I. (2001). Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arteriosclerosis, thrombosis, and vascular biology, 21(9), 1451-1457.
• [7] Teiber, J. F., Draganov, D. I., & La Du, B. N. (2003). Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochemical pharmacology, 66(6), 887-896.
• [8] Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G., & James, R. W. (2002). Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. Journal of Biological Chemistry, 277(6), 4301-4308.
• [9] Mackness, B., Durrington, P. N., & Mackness, M. I. (1998). Human serum paraoxonase. General Pharmacology: The Vascular System, 31(3), 329-336. [10] Gugliucci, A., Kotani, K., & Kimura, S. (2012). Paraoxonase 1 in chronic kidney failure. Journal of Lipids, 2012.
• [11] Ikeda, T., Obayashi, H., Hasegawa, G., Nakamura, N., Yoshikawa, T., Imamura, Y., ... & Kinoshita, S. (2001). Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. American journal of ophthalmology, 132(2), 191-195.
• [12] Roy, I., & Gupta, M. N. (2002). Three-phase affinity partitioning of proteins. Analytical Biochemistry, 300(1), 11-14.
• [13] Narayan, A. V., Madhusudhan, M. C., & Raghavarao, K. S. M. S. (2008). Extraction and purification of Ipomoea peroxidase employing three-phase partitioning. Applied biochemistry and biotechnology, 151(2), 263-272.
• [14] Keskin, S. Y., & Büşra, K. A. T. (2013). İnvertaz Enziminin Üçlü Faz Sistemi İle Saflaştırılması Ve Termal Kararlılığının İncelenmesi. Sakarya Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 17(2), 291-294.
• [15] Duman, Y., & Kaya, E. (2014). Purification and recovery of invertase from potato tubers (Solanum tuberosum) by three phase partitioning and determination of kinetic properties of purified enzyme. Turkish Journal of Biochemistry/Turk Biyokimya Dergisi, 39(4).
• [16] Sagu, S. T., Nso, E. J., Homann, T., Kapseu, C., & Rawel, H. M. (2015). Extraction and purification of beta-amylase from stems of Abrus precatorius by three phase partitioning. Food chemistry, 183, 144-153.
• [17] Vetal, M. D., & Rathod, V. K. (2015). Three phase partitioning a novel technique for purification of peroxidase from orange peels (Citrus sinenses). Food and Bioproducts Processing, 94, 284-289.
• [18] Türkeş, C., Söyüt, H., & Beydemir, Ş. (2014). Effect of calcium channel blockers on paraoxonase-1 (PON1) activity and oxidative stress. Pharmacological reports, 66(1), 74-80.
• [19] Alim, Z., & Beydemir, Ş. (2016). Some anticancer agents act on human serum Paraoxonase‐1 to reduce its activity. Chemical biology & drug design, 88(2), 188-196.
• [20] Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry, 72(1-2), 248-254.
• [21] Özer, B., Akardere, E., Çelem, E. B., & Önal, S. (2010). Three-phase partitioning as a rapid and efficient method for purification of invertase from tomato. Biochemical engineering journal, 50(3), 110-115.
• [22] Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. nature, 227(5259), 680-685.
• [23] Demir, Y., Işık, M., Gülçin, İ., & Beydemir, Ş. (2017). Phenolic compounds inhibit the aldose reductase enzyme from the sheep kidney. Journal of biochemical and molecular toxicology, 31(9), e21936.
• [24] Başkol, G., & Köseoğlu, K. (2004). Paraoxanase: biochemical features, functions and clinical importance. Erciyes Medical Journal, 26(2), 75-80.
• [25] Demira, N., & Nadaroğlub, H. (2011). An, In Vitro, Study of some Pesticides on the Activity of Human Serum Paraoxonase (PON1). Jordan Journal of Chemistry Vol, 6(4), 439-451.
• [26] Erzengin, M., Basaran, I., Cakir, U., Aybey, A., & Sinan, S. (2012). In vitro inhibition effect of some dihydroxy coumarin compounds on purified human serum paraoxonase 1 (PON1). Applied biochemistry and biotechnology, 168(6), 1540-1548.
• [27] Sinan, S., Kockar, F., & Arslan, O. (2006). Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie, 88(5), 565-574.
• [28] Renault, F., Chabrière, E., Andrieu, J. P., Dublet, B., Masson, P., & Rochu, D. (2006). Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography. Journal of Chromatography B, 836(1-2), 15-21.
• [29] Demir, N., Nadaroğlu, H., & Demir, Y. (2008). Purification of human serum paraoxonase and effect of acetylsalicylic acid on paraoxonase activity. Pharmaceutical Biology, 46(6), 393-399. [30] Kanamori-Kataoka, M., & Seto, Y. (2009). Paraoxonase activity against nerve gases measured by capillary electrophoresis and characterization of human serum paraoxonase (PON1) polymorphism in the coding region (Q192R). Analytical biochemistry, 385(1), 94-100.
• [31] Türkeş, C. (2019). A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors. Journal of Pharmacy and Pharmacology, 71(10), 1553-1564.
• [32] Işık, M., Beydemir, Ş., Demir, Y., Durgun, M., Türkeş, C., Nasır, A., ... & Akkuş, M. (2020). Benzenesulfonamide derivatives containing imine and amine groups: Inhibition on human paraoxonase and molecular docking studies. International journal of biological macromolecules, 146, 1111-1123.
• [33] Sayın, M., & Guler, O. O. (2015). Purification of bovine serum paraoxonase and its immobilization on Eupergit C 250 L by covalent attachment. Journal of enzyme inhibition and medicinal chemistry, 30(1), 69-74.
• [34] Aşkın, U., Karataş, F., Türköz, Y., & Aydın, S. (2012). Paraoksonaz-1 enziminin bazı kinetik özelliklerinin incelenmesi ve ghrelin hormonu ile ilişkisi.
• [35] Rodrigo, L., Hernández, A. F., Lopez-Caballero, J. J., Gil, F., & Pla, A. (2001). Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chemico-biological interactions, 137(2), 123-137.
• [36] Lineweaver, H., & Burk, D. (1934). The determination of enzyme dissociation constants. Journal of the American chemical society, 56(3), 658-666.